# US 2008/0313753 A1 · Compositions and Methods for Improving Heart Function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0313753 A1
- Document ID: US20080313753A1
- Status: Published application
- Kind: A1
- Application number: 11/574,232
- Filed: 2005-08-25
- Published: 2008-12-18
- Earliest claimed: 2004-08-25
- Assignees: The Regents of the University of California
- Inventors: Wolfgang Dillmann; Darrell H. Belke; Ying Hu; Raymond Clark
- Web page: https://patentgrep.com/patent/US20080313753A1

## CPC

- C12N 9/1051: {Hexosyltransferases (2.4.1)}
- A61K 38/45: Transferases (2)
- C12Y 204/0115: N-Acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (2.4.1.150)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present invention relates to treating or ameliorating heart disease associated with poor myocardial performance, e.g., diabetic cardiomyopathy and associated disorders, particularly to treating, preventing or ameliorating such disorders through inhibition of O-GlcNAcylation and/or increased activity of O-GlnNAcase. The invention provides vectors for gene transfer of O-GlnNAcase. In one aspect, the invention provides cells, vectors, formulations comprising them and methods of using them, for the gene transfer of the human O-GlnNAcase gene, e.g., to treat conditions and diseases associated with impaired cardiac contractility, such as that, found associated with diabetic cardiomyopathy. In another aspect, the invention provides non-human transgenic animals and host cells comprising genetically engineered cells having increased activity of O-GlnNAcase.

## Claims

### Claim 1

A method for decreasing the calcium transient (T1/2) intracellular calcium flux in a myocyte under hyperglycemic or diabetic conditions comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte, thereby decreasing the calcium transient (T1/2);
(ii) the method of (i), wherein the diabetic condition is a type I diabetes or type II diabetes, or the hyperglycemic or diabetic conditions is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 2

A method for ameliorating diastolic impairment in calcium flux in a diabetic heart comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the heart, thereby ameliorating diastolic impairment in calcium flux;
(ii) the method of (i), wherein the diabetic condition is type I diabetes or type II diabetes, or the diabetic heart is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 3

A method for improving (normalizing) calcium cycling in a myocyte under hyperglycemic or diabetic conditions, or a diabetic heart, by enhancing the Ca2+ transient and sarcoplasmic reticulum Ca2+ loading, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or heart, thereby enhancing the Ca2+ transient and sarcoplasmic reticulum Ca2+ loading in the myocyte or heart;
(ii) the method of (i), wherein the hyperglycemic or diabetic conditions, or diabetic heart, is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 4

A method for lowering PLB expression in a myocyte under hyperglycemic or diabetic conditions, or in a diabetic heart, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or the heart, thereby lowering PLB expression in the myocyte or the heart;
(ii) the method of (i), wherein the diabetic heart, or hyperglycemic or diabetic conditions is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 5

A method for increasing or normalizing SERCA2a expression, SERCA2a/PLB ratio and/or SERCA2a activity in a myocyte under hyperglycemic or diabetic conditions, or in a diabetic heart, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or the heart, thereby increasing or normalizing SERCA2a expression, SERCA2a/PLB ratio and/or SERCA2a activity in the myocyte or the heart;
(ii) the method of (i), wherein the hyperglycemic or diabetic conditions, or diabetic heart, is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 6

A method for increasing or normalizing phosphorylation levels of PLB in a myocyte under hyperglycemic or diabetic conditions, or in a diabetic heart, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or the heart, thereby increasing or normalizing SERCA2a expression, SERCA2a/PLB ratio and/or SERCA2a activity in the myocyte or the heart;
(ii) the method of (i), wherein the hyperglycemic or diabetic conditions, or diabetic heart, is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 7

A method for increasing or normalizing SERCA2a promoter activity in a myocyte under hyperglycemic or diabetic conditions, or in a diabetic heart, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or the heart, thereby increasing or normalizing SERCA2a promoter activity in the myocyte or the heart;
(ii) the method of (i), wherein the diabetes is type I diabetes or type II diabetes, or the hyperglycemic or diabetic conditions is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 8

A method for reducing cellular O-GlcNAcylation in a myocyte under hyperglycemic or diabetic conditions, or in a diabetic heart, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or the heart, thereby reducing cellular O-GlcNAcylation in the myocyte or the heart;
(ii) the method of (i), wherein the hyperglycemic or diabetic conditions, or diabetic heart, is caused by type I diabetes or type II diabetes;
(iii) wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 9

A method for reducing transcription factor Sp1 O-GlcNAcylation and increasing Sp1 activity in a myocyte under hyperglycemic or diabetic conditions, or in a diabetic heart, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or the heart, thereby reducing transcription factor Sp1 O-GlcNAcylation and increasing Sp1 activity in the myocyte or the heart;
(ii) the method of (i), wherein the hyperglycemic or diabetic conditions, or diabetic heart, is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 10

A method for normalizing myocyte-specific enhancer factor-2 (MEF-2a) levels in a myocyte under hyperglycemic or diabetic conditions, or in a diabetic heart, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in the myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or the heart, thereby normalizing the MEF-2a levels in the myocyte or the heart;
(ii) the method of (i), wherein the hyperglycemic or diabetic conditions, or diabetic heart, is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 11

A method for improving or normalizing cardiomyocyte contractility in a diabetic heart, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in a myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or the heart, thereby improving or normalizing cardiomyocyte contractility in the heart;
(ii) the method of (i), wherein the hyperglycemic or diabetic conditions, or diabetic heart, is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim 12

A method for improving or normalizing global contractility in a diabetic heart, the method comprising
(i) (a) providing a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in a myocyte or the heart, or an O-GlcNAc (OGT) protein; and
(b) administering an effective amount of the nucleic acid or OGT protein to the myocyte or the heart, thereby improving or normalizing global contractility in the heart;
(ii) the method of (i), wherein the diabetes is type I diabetes or type II diabetes, or the hyperglycemic or diabetic conditions is caused by type I diabetes or type II diabetes;
(iii) the method of (i) or (ii), wherein administering the effective amount of the nucleic acid or OGT protein causes reduction of excessive O-GlcNAcylation in cytosolic and/or nuclear proteins;
(iv) the method of any of (i) to (iii), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(v) the method of (iv), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(vi) the method of (iv), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim at position 13

13-14. (canceled)

### Claim 15

A method for improving myocardial performance (contractility) or global heart contractility in a mammal comprising a step of enhancing or increasing O-linked GlcNAc transferase (O-GlcNAc, OGT) transferase (O-GlcNAcase, O-GlcNAc, OGT) activity, the method comprising
(i) (a) providing (i) a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in a myocyte or the heart, (ii) an O-GlcNAc (OGT) protein, (iii) a compound that relieves inhibition of O-GlcNAc (OGT) activity; or (iv) a compound that increases O-GlcNAc (OGT) transcription; and
(b) administering an effective amount of the nucleic acid, protein or compound of (a) to the heart, thereby improving myocardial performance or global heart contractility in the heart;
(ii) the method of (i), wherein the mammal is diabetic, or the mammal is a diabetic human; or
(iii) the method of (i) or (ii), wherein the mammal is a mouse, a rat, a rabbit, a hamster, a dog, a pig, a sheep or a monkey;
(iv) the method of any of (i) to (iii), wherein the compound that increases O-GlcNAc (OGT) transcription comprises a transcriptional regulatory nucleic acid, and the method comprises inserting the transcriptional regulatory nucleic acid into the genome of a cell such that it increases transcription of O-GlcNAc (OGT) endogenous to the cell or relieves transcriptional inhibition of O-GlcNAc (OGT) endogenous to the cell; or
(v) the method of (iv), wherein the transcriptional regulatory nucleic acid comprises a promoter or an enhancer.

### Claim at position 15

16-17. (canceled)

### Claim 18

A method for improving myocardial performance (contractility) or global heart contractility in a diabetic mammal or a hyperglycemic mammal comprising
(i) (a) providing a pharmaceutical composition comprising (i) a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in a myocyte or the heart, (ii) an O-GlcNAc (OGT) protein, (iii) a compound that relieves inhibition of O-GlcNAc (OGT) activity; or (iv) a compound that increases O-GlcNAc (OGT) transcription; and
(b) administering an effective amount of the pharmaceutical composition to a subject in need thereof, thereby improving the myocardial performance (contractility) or global heart contractility in the diabetic mammal or hyperglycemic mammal;
(ii) the method of (i), wherein the compound that increases O-GlcNAc (OGT) transcription comprises a transcriptional regulatory nucleic acid, and the method comprises inserting the transcriptional regulatory nucleic acid into the genome of a cell such that it increases transcription of O-GlcNAc (OGT) endogenous to the cell or relieves transcriptional inhibition of O-GlcNAc (OGT) endogenous to the cell; or
(iii) the method of (ii), wherein the transcriptional regulatory nucleic acid comprises a promoter or an enhancer.

### Claim 19

A method for treating, ameliorating or preventing heart disease comprising poor myocardial performance associated with diabetic cardiomyopathy, comprising
(i) (a) providing a pharmaceutical composition comprising (i) a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in a myocyte or the heart, (ii) an O-GlcNAc (OGT) protein, (iii) a compound that relieves inhibition of O-GlcNAc (OGT) activity; or (iv) a compound that increases O-GlcNAc (OGT) transcription; and
(b) administering an effective amount of the pharmaceutical composition to a subject in need thereof, thereby treating, ameliorating or preventing heart disease comprising poor myocardial performance associated with diabetic cardiomyopathy;
(ii) the method of (i), wherein the subject is a diabetic mammal, and optionally the mammal is a human, a mouse, a rat, a rabbit, a hamster, a dog, a pig, a sheep or a monkey;
(iii) the method of (i) or (ii), wherein the compound that increases O-GlcNAc (OGT) transcription comprises a transcriptional regulatory nucleic acid, and the method comprises inserting the transcriptional regulatory nucleic acid into the genome of a cell such that it increases transcription of O-GlcNAc (OGT) endogenous to the cell or relieves transcriptional inhibition of O-GlcNAc (OGT) endogenous to the cell; or
(iv) the method of (iii), wherein the transcriptional regulatory nucleic acid comprises a promoter or an enhancer.

### Claim at position 18

20-21. (canceled)

### Claim 22

An ex vivo method for treating, ameliorating or preventing heart disease comprising poor myocardial performance associated with diabetic cardiomyopathy comprising
(i) (a) providing a cardiomyocyte, cardiomyocyte precursor cell or cardio-myocyte stem cell that overexpresses O-linked GlcNAc transferase (O-GlcNAc, OGT) by (i) inserting into the myocyte a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in a myocyte or the heart, (ii) inserting into the myocyte an O-GlcNAc (OGT) protein, (iii) inserting into the myocyte a compound that relieves inhibition of O-GlcNAc (OGT) activity; (iv) inserting into the myocyte a compound that increases O-GlcNAc (OGT) transcription; or (v) inserting into the myocyte a transcriptional regulatory nucleic acid that it increases transcription of O-GlcNAc (OGT) endogenous to the cell or relieves transcriptional inhibition of O-GlcNAc (OGT) endogenous to the cell; and
(b) administering the cardiomyocyte, cardiomyocyte precursor cell or cardio-myocyte stem cell to the heart of a subject in need thereof, thereby treating, ameliorating or preventing heart disease comprising poor myocardial performance associated with diabetic cardiomyopathy;
(ii) the method of (i), wherein an O-linked GlcNAc transferase (O-GlcNAc, OGT) nucleic acid is contained within a cloning vehicle, an expression cassette or vector;
(iii) the method of (ii), wherein the cloning vehicle, expression cassette or vector comprises a viral vector, a plasmid, a phage, a phagemid, a cosmid, a fosmid, a bacteriophage or an artificial chromosome; or
(iv) the method of (iii), wherein the viral vector comprises an adenovirus vector, a retroviral vector or an adeno-associated viral vector, wherein optionally the retroviral vector comprises a lentiviral vector.

### Claim at position 20

23-25. (canceled)

### Claim 26

A pharmaceutical composition formulated for treating, ameliorating or preventing heart disease comprising poor myocardial performance associated with diabetic cardiomyopathy, comprising (i) a nucleic acid encoding an O-linked GlcNAc transferase (O-GlcNAc, OGT), wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in a myocyte or the heart, (ii) an O-GlcNAc (OGT) protein, (iii) a compound that relieves inhibition of O-GlcNAc (OGT) activity; or (iv) a compound that increases O-GlcNAc (OGT) transcription.

### Claim 27

An isolated cardiomyocyte cell, cardiomyocyte precursor cell or cardio-myocyte stem cell comprising:
(a) a nucleic acid encoding (i) an O-linked GlcNAc transferase (O-GlcNAc, OGT), (ii) an exogenous O-GlcNAc (OGT) protein, (iii) a compound that relieves inhibition of O-GlcNAc (OGT) activity; and/or (iv) a compound that increases O-GlcNAc (OGT) transcription,
wherein the nucleic acid is operatively linked to a promoter constitutively or inducibly active in a myocyte or the heart; or
(b) the isolated cardiomyocyte cell, cardiomyocyte precursor cell or cardio-myocyte stem cell of (a), wherein the cell and/or the O-linked GlcNAc transferase (O-GlcNAc, OGT) are derived from a human.

### Claim 28

(canceled)

### Claim 29

A non-human transgenic animal comprising
(i) a heterologous O-linked GlcNAc transferase (O-GlcNAc, OGT) coding sequence;
(ii) the non-human transgenic animal of (i), wherein the animal is a goat, a rabbit, a sheep, a pig, a dog, a cow, a cat, a rat or a mouse; or,
(iii) the non-human transgenic animal of (i) or (ii), wherein the endogenous O-linked GlcNAc transferase (O-GlcNAc, OGT) gene of the non-human transgenic animal is completely or partially disabled (“knocked out”).

### Claim at position 25

30-31. (canceled)

### Claim 32 (depends on 29)

A cell derived from the non-human transgenic animal of claim 29.

### Claim 33 (depends on 29)

A cell line derived from the non-human transgenic animal of claim 29.

### Claim 34 (depends on 29)

A tissue derived from the non-human transgenic animal of claim 29.

### Claim 35 (depends on 30)

An inbred mouse line derived from the cell line of claim 30.

### Claim 36 (depends on 35)

The inbred mouse line of claim 35, wherein the mouse line comprises a human an O-linked GlcNAc transferase (O-GlcNAc, OGT).
